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BENEFITS AND RISKS IN HRT
The effectiveness of estrogen replacement therapy
(ERT) for relief of vasomotor symptoms such as hot
flash and vaginal atrophy and for prevention of bone
loss in postmenopausal and bilaterally ovariectomized
women is well established (1-3). In postmenopausal
women with hypercholesterolemia, estrogen is effective
for reducing the levels of total cholesterol and low-
density lipoprotein-cholesterol (LDL-C) and for in-
creasing the level of high-density lipoprotein-cholesterol
(HDL-C)(4, 5). Supplementation of estrogenwas also
demonstrated to improve endothelium - dependent
vasodilatation in postmenopausal women due to aug-
mentation of nitric oxide production (6). In addition,
estrogen was reported to be associated with reduced
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risk of Alzheimer’s disease (7). In women with an
intact uterus, treatment with estrogen and progestin
as hormone replacement therapy (HRT) is needed
to reduce the incidence of endometrial hyperplasia
observed with unopposed estrogen and to reduce
the risk of endometrial cancer.
In USA and several countries in Europe,more than
30% of postmenopausal women are receiving HRT.
However, compliancewithHRThas been reported to be
low despite the various benefits of HRT. Many studies
have shown that a large percentage of postmenopausal
women receiving HRT discontinue treatment within
5 years. Thorp et al . reported that only 42% of new
HRT drug users continuously took HRT drugs during
the first year (8). Ettinger et al . demonstrated that
the probability of continuation in older women aged
65 years or older was only 38% after 12 months treat-
ment (9). MacLennan et al. reported that the ratio of
current and past use of HRT drugs in South Australian
women was 50 to 60% (10). In addition, the rate of long-
term compliance was shown to be lower. Purdie re-
ported that only 48% of women who started HRT were
continuing 2 years later (11). Coope et al . reported
that only 15% of women had continued HRT for over
5 years (12). The most common reasons for discon-
tinuation of HRT have been reported to be side effects
such as uterine bleeding, breast tenderness, fear of
cancer and anxiety about thrombosis (9, 13).
In Japan, the total sales of estrogen products have
increased threefold over the past decade. However,
the percentage of postmenopausal women receiving
HRT is still smaller than the percentages in Europe and
USA. In the Department of Obstetrics andGynecology
of Tokushima University Hospital, the rates of com-
pliance with HRT after one, three and five years in
postmenopausal and bilaterally ovariectomized women
treated with HRT were 65.4%, 48.5% and 36.9%, respect-
ively (14). The compliance rate was significantly lower
in women with an intact uterus than in hysterectomized
women. In addition, the rate of early discontinuation
of HRT was high ; 43% of thewomen discontinuedHRT
after only one visit to our out-patient clinic. Anxiety
about HRT and no relief of symptomswere themajor
reasons for stopping HRT in the first year after begin-
ning HRT, while the percentage of women who dis-
continued HRTdue to side effects such as unacceptable
uterine bleeding and breast tenderness increased
after one year of HRT.
REPORTS OF THE WOMEN’S HEALTH
INITIATIVE
Several recent large-scale randomized clinical trials
such as theHeart andEstrogen/Progestin Replacement
Study (HERS) and the Estrogen Replacement and
Atherosclerosis (ERA) trial have shown that there is
no apparent benefit of HRT for risk of atherosclerosis
and that protection from cardiovascular disease is not
an indication for theuseofHRT inpostmenopausalwomen
(15, 16). The Women’s Health Initiative (WHI) trial, a
randomized controlled primary prevention trial in which
16,608 postmenopausal women(50-79yr. old)with intact
uteri participated, was stopped in July, 2002 on the basis
of assessment that the overall health risks exceeded
health benefits after an average follow-up period of
5.2 years (17). As shown in Table1, this planned 8.5-
year randomized clinical trial showed that women taking
estrogen (conjugated equineestrogen :CEE)at adosage
of 0.625mg/day and progestin (medroxyprogesterone
acetate : MPA) at a dosage of 2.5mg/day were at in-
creased risk for myocardial infarction, stroke, venous
thromboembolism and breast cancer compared with
women taking a placebo. Although thereweredecreased
risks of osteoporotic fractures and colorectal cancer
in the hormone treatment group, an unfavorable global
risk-benefit profile was found in this group.The estrogen-
alone trial is scheduled to continue until March, 2005.
Moreover, theUKMedicalResearchCouncil announced
that theWomen’s International Study of long Duration
Oestrogen after Menopause (WISDOM) had to be
stopped in October, 2002 for scientific and practical
reasons (18).
In the WHI trial, only one drug regimen, CEE at a
dosage of 0.625mg/day andMPA at a dosage of 2.5mg/
day, was tested in postmenopausal women. In the report
Table１．Clinical outcomes
Outcomes Hazard ratio
Coronary heart disease
Stroke
Venous thromboembolic disease
Invasive breast cancer
Colorectal cancer
Hip fracture
１．２９
１．４１
２．１１
１．２６
０．６３
０．６６
Global index １．１５
The global index represents the first event for each participant
from among the following types : CHD, stroke, pulmonary embolism,
breast cancer, endometrial cancer, colorectal cancer, hip fracture
and death due to other causes. (Writinggroup for theWHI investigators,
JAMA 288, 2002)
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presenting results of theWHI, itwas statedas a limitation
of the study that the resultsdonotnecessarilyapplyto lower
dosages of these drugs or to estrogens and progestins
administered through the transdermal route. Several
problems characteristic of the subjects in this trial were
also discussed in that report. The womenwho enrolled
in the WHI trial were 50 to 79 years old at the time of
recruitment, but participants were not typical users
of HRT drugs. In theWHI trial, 36% of the womenwho
underwent HRT had hypertension, 49%were current or
past smokers and 34% were obese (body mass index＞
30kg/m2). Therefore, not all women were healthy.
Further analysis of the WHI data may be necessary.
LOW-DOSE HRT
The most commonly prescribed estrogen forHRT is
conjugated equine estrogen (CEE : Premarin,Wyeth),
which is usually taken orally at a dosage of 0.625mg/
day. Medroxyprogesterone acetate (MPA : Provera,
Upjohn) for endometrial protection is the most com-
monly used progestin for HRT, with typical dosages
of 2.5mg/day when taken daily and 5 to 10mg/day for
a cycle of 10 to 14 dayswhen administered sequentially.
CEE was reported to be effective in preventing bone
loss and reducing fracture rates when given orally at
a daily dose of 0.625mg, and relatively small doses of
CEE (less than 0.625mg/day) were originally found to
be ineffective in preventing osteoporosis (19). However,
recent studies have demonstrated that low-doseHRT
is safe and effective for prevention of postmenopausal
bone loss (20, 21). Dosages of estrogens that are con-
sidered to be low are shown in Table 2 (20). Ettinger
et al . andWebber et al. demonstrated that CEE at adaily
dose of 0.31mg with calcium supplementation of 1,000
mg/day was effective inpreventingpostmenopausal bone
loss (22, 23).Mizunuma et al. reported that HRT using
0.31 mg of CEE can increase lumbar bone mineral
density (BMD) in Japanese postmenopausal women
(24). Recker et al. demonstrated that continuous low-
dose HRTwithCEE(0.3mg)andMPA(2.5mg)combined
with adequate calcium and vitaminD
supplementationprovidesabone-sparing
effect that is similar or superior to that
provided byhigher-doseHRTregimens
in elderlypostmenopausalwomen (25).
Prestwood et al. also reported that low-
dose estrogen treatment with calcium
and vitaminDdecreasedboneresorption
and increasedbonemassinolderwomen
(26). As shown in Figure 1, Lindsay
et al ., who recently carriedout a large-
scale, randomized, placebo-controlled
study, demonstratedthat lowerdosesof
CEEs (0.45 and0.3mg/day)prevented
the loss of spine and hip BMD and
reduced bone turnover (27).
Fig.1. Spine bone mineral density changes for
modified intention-to-treat and efficacy-evaluable
populations forconjugatedequineestrogens(CEEs)
alone and CEEs-medroxyprogesterone acetate
(MPA) groups.
Adjustedmean percentage changes (SE) in spine
BMDovertimeareshownforthemodified intention-
to-treat (A andC) andefficacy-evaluable (BandD)
populations for both the CEEs alone (A, B) and
CEEs-MPA groups (C, D). The placebogroup is
displayed in all graphs.Changesweresignificantly
different (p<0.05) frombaseline andplaceboforall
active treatment groups at all time points.
(Lindsay et al., JAMA 287, 2002)
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Fig.2. Mean daily number of hot flashes by week are shown for the eight treatment groups. A:The placebo and the CEE alone
groups. B : The placebo and the CEE/MPA groups. Data are adjusted for baseline. All values for mean number of hot flashes
(unadjusted) were significantly less than baseline (p<0.05), except CEE 0.3/MPA 1.5 at week one.
*Difference from placebo was significant (p<0.05) from weeks 2 through 12.
†Difference from placebo was significant (p<0.05) from weeks 3 through 12.
‡Difference from CEE 0.45 and CEE 0.45/MPA 2.5 was significant (p<0.05) at weeks 3,4,5 and 9.
§Difference between CEE 0.625 and CEE 0.45 was significant (p<0.05) from weeks 2 through 12.
‖Difference between CEE 0.625 and CEE 0.3 was significant (p<0.05) at weeks 4,5,6,9,10 and 12.
(Utian et al ., Fertil Steril 75, 2001)
Fig.3.Mean percent changes from baseline (±SE) are shown for HDL -C (left panel) and LDL -C (right panel) for all treatment
groups after cycle 6 and cycle 13.*p<0.05 vs. baseline ; †p<0.05 vs. placebo ; ‡p<0.05 vs. comparable dose of CEE alone
(Lobo et al ., Fertil Steril 7６, 2001)
Table２．Low-dose estrogen preparations
Estrogen Dosage (mg/day)
Oral
Conjugated equine estrogen
Esterified estrogen
Micronized estradiol
0.3
0.3
0.5
Transdermal 17 β-Estradiol 0.025
Differences of opinion exist on estrogen dosages that qualify as “low dose”. In the USA, dosages below
0.625 mg conjugated equine estrogens (CEE)(or equivalent) are generally considered low dose. Outside
the USA, some clinicians define therapy with 0.625mg/day CEE (or equivalent) as low-dose. (Lobo et al.,
Climacteric 4, 2001)
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Low-dose HRT was also effective in decreasing the
number and severity of hot flashes and in improving
vaginal atrophy in postmenopausal women (Fig.2)(28)
in addition to inducing favorable changes in lipids, lipo-
proteins and hemostatic factors (Fig.3)(29). A recent
Nurses Health Study report noted that administration
of low-doseHRT reduced the incidenceof cardiovascular
disease (30). Sanada et al. reported that low-dose CEE
plus MPA similar to conventional-dose CEE plusMPA
augmented endothelial function in forearm resistance
arteries and decreased malondialdehyde-modified LDL
levels (31). Goudev et al. revealed that low-doseHRT
with 17β-estradiol and norethisterone acetate reduced
the serum levels of intercellular adhesion molecules,
vascular cell adhesionmolecules and P-selectin, which
are associatedwith cardiovascular risk (32).Moreover,
low-dose regimens of CEE and MPA result in higher
rates of amenorrhea, no bleeding and endometrial
protection compared with 0.625mg CEE and 2.5mg
MPA per day (33, 34). These findings suggest that low-
dose HRTmay improve the complianceratebecause low-
dose HRT causesminimal spottingandbreast tenderness
and lessprogestogen-relatedadverse effects andpossibly
reduces the risk of cancer. The establishment of low-
dose formulaions with potentially fewer side effects
is important for enhancing patient acceptance and
continuance of HRT. Recently, low-doseHRThas also
been shown to result in a better quality of life (35).
In Japan, CEEat adosageof 0.3125mgwasnot available
in principle. Serum estradiol levels in subjects in the
present study who were treated with CEE and MPA
every other day were found to be significantly lower
than those in subjects whowere treatedeveryday (36),
and treatment with CEE andMPAevery other day could
be regarded as low-dose HRT. We showed that HRT
with CEE and MPA every other day was effective for
relieving vasomotor symptoms and preventing bone
loss andwas associatedwith fewer side effects, such as
unscheduled bleeding or breast tenderness, while it
showed no beneficial effects on lipid profile (36). HRT
administered every other day at a low dose is also a
choice of treatment for preventingunscheduleduterine
bleeding and breast tenderness.
TRANSDERMAL ESTROGENTREATMENT
Estrogenadministered transdermallyhasbeen shown
to reduce the incidence and severity of hot flashes (37).
Long-term treatment with transdermal estrogen has
been effective for preventingosteoporosis (38).However,
the effect of transdermal estrogen therapy on lipid
metabolism was reported to beweak because estrogen
administered transdermally is absorbed directly into
the systemic circulation, avoiding hepatic first-pass
metabolism, while estrogen administered orally directly
enters hepatic circulation and affects lipid metabolism
in the liver. Thus, changes in lipid profiles in the case
of treatment with transdermal estrogen are smaller
than those in the case of treatment with oral estrogen.
On the other hand, hypertriglyceridemia is also a risk
factor for coronary heart disease. McNamara et al. sug-
gested that the plasma triglyceride level is the singlemost
important factor affecting the size of LDL particles (39).
Oral estrogen therapywithCEEwas reported to increase
the plasma concentration of triglyceride and reduce
the size of LDL particles, while transdermal estrogen
therapy was demonstrated to decrease the plasma
concentration of triglyceride and increase the size of
LDL particles (40). Small sizes of LDL particles are
associated with increased risk of coronary heart disease
because they are more susceptible to oxidative modifi-
cation, an initial step in the atherosclerotic process.
Thus, transdermal estrogen treatment is recommended
for postmenopausal womenwith hypertriglyceridemia.
ESTROGEN THRESHOLD HYPOTHESIS
The serum estradiol level was reported to be closely
related to the estrogenic effects on various tissues
(41, 42). As shown in Fig.4, the hierarchy of the most-
sensitive to least-sensitive estrogen-responsive process
is in the order of calcium turnover, gonadotropin secre-
tion, vasomotor symptoms, vaginal epithelial growth,
lipid production and liver protein production such as
sex hormone-binding globulin production (41). In a
similar manner, estradiol-dependent disease processes
also appear to have a hierarchy of responsiveness to
estradiol. Breast cancer can be very sensitive to the
growth-promoting effect of estradiol at concentrations
as low as 10 to 20pg/ml. To reducemyoma volume in
premenopausal women by 50%, serumestradiol concen-
trations in the range of 15 to 25pg/mlmust be achieved.
A serumestradiol level about 30pg/ml induces regression
of endometriotic lesions. The hierarchy of the most-
sensitive to least-sensitive estrogen-response disease
processes appears to be inorderofbreast cancer,myomas
and endometriosis.
A relation between estradiol level and BMD of the
lumbar spine in postmenopausal womenwho have been
continuously taking esterified estrogen medication
has been demonstrated (43). However, it is not known
whether there is a relation between serumestradiol level
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and BMD in women treated with CEE. CEE, which is
the most commonly prescribed drug forHRTworldwide,
is a unique complex of at least 10natural estrogens.
Thus, precise measurement of serum estradiol levels
in women receiving oral CEE is difficult. For postmeno-
pausal women receiving CEE for HRT, extraction of sex
steroid hormones from serumbefore theassay is needed
for measurement of serum levels of estradiol.We have
developed a highly sensitive and specific assay using
high-performance liquid chromatography (HPLC) for
purification and a radioimmunoassay (RIA) formeasure-
ment of serumestrone and estradiol levels, and reported
the precise levels of estrone and estradiol in women
undergoing oral CEE treatment (44). Themean serum
estradiol level measured by HPLC-RIA was 22.8pg/
ml, while that measured using a conventional RIA kit
was 76.2 pg/ml. We also measured serum levels of
estradiol in postmenopausal women receiving CEE
(0.625mg) andMPA (2.5mg) every other day andevery
day, and we showed that there was a relation between
serum estradiol level and BMD of the lumbar spine
(45).
ENDOGENOUS ESTROGEN
The need for estrogen replacement therapy may
depend on the amount of endogenous estrogen being
synthesized and estrogen threshold for a relevant organ
(e.g., brain, boneandheart).Thus, the level of endogenous
estrogen is also an important factor in the administration
of exogenous estrogen such asHRT. Endogenous estro-
gen level is known to be closely relatedwith bodymass
index (46). Womenwhoareheavier orwhohaveagreater
body mass index have been reported to have higher
levels of estrogen, due to the aromatization of gonadal
steroid hormone precursors in fat and muscle tissue
(47-50).
Recent studies using highly sensitive methods to
measure serum estradiol levels have provided evidence
of beneficial effects of very low levels of circulating estro-
gens on bone. Cummings et al. found that women 65
years of age or older with low but detectable levels of
serum estradiol (ranging from5 to 9 pg/ml)hada signifi-
cantly lower risk of hip or vertebral fractures than did
women with undetectable levels (less than 5pg/ml)
(51). In a different sample of women randomly selected
from the same cohort, Ettinger et al. found that women
with estradiol levels below 5pg/ml had substantially
less BMD at all sites measured than did women with
levels in the range of 10 to 25pg/ml (52). Thus, higher
endogenous estradiol levels are associatedwith increased
bone density, reduced bone loss and reduced fracture
incidence in elderly women. In addition, lowendogenous
estradiol levels in postmenopausal womenwere found
to be related to appearance of hot flash (53).On theother
hand, the relative risk for breast cancer in womenwith
very high endogenous estradiol levels was significantly
higher than that in women with very low estradiol
levels (54). The results of the MORE trial showed that
the risk of breast cancer in womenwith an endogenous
estradiol level of greater than 10pmol/l was higher
than that in women with an undetectable estradiol
level (55).
The relation between endogenous estrogen and
its effect on various tissues in Japanese postmenopausal
women is not clear. We precisely measured the level
of endogenous estrogen by the HPLC-RIA method
whose sensitivity of estrone and estradiol levels was
5 and 2pg/ml, respectively. A study of the relation be-
tween endogenous estrogen level and BMD of the
lumbar spine in postmenopausal women revealed that
Fig.4. Hierarchy of tissueanddisease response
to various concentrations.Calciummetabolism
and bone may be more sensitive to estradiol
than vaginal epithelium and lipidmetabolism.
TBG : thyroid-binding globulin ;CBG:cortisol-
binding globulin ; SHBG:sexhormone-binding
globulin
(Barbieri et al ., Am J Obstet Gynecol 166,
1992)
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women with estradiol levels below 2pg/ml for whom
more than 5years had passed since menopause had
less spine BMD than didwomenwith levels in the range
of 10 to 20pg/ml (Fig.5)(56).
INDIVIDUALIZED HRT
It was reported that ERT reduces the risk of eden-
tulism and protects against loss of teeth (57). ERT
was also reported to have a protective effect on lenses
in postmenopausal women (58). In addition, Zandi
et al . suggested that the higher risk of Alzheimer’s
disease for women than formen in old agemight disap-
pear if womenwere to undergo long-term postmenpausal
HRT (Fig.6)(59). Thus, there is great interest in further
development of low-doseHRTand transdermal estrogen
therapy. These regimenswith fewer side effects in addi-
tion to various effects on several tissues, will be impor-
tant for the future of HRT.
An appropriate HRT regimen should be selected to
suit the individual in terms of risks, benefits and prefer-
ences (60). Various basic characteristics of individuals
such as endogenous estrogen level, BMI, smoking and
the state of glucosemetabolismare important, and selec-
tion of the most appropriate regimen of HRT (dose,
route of administration and schedule) for the needs of
the individual are important factors for continuation of
HRT. Alternative treatments, suchasherbalmedicinesand
soy proteins for improvement of vasomotor symptoms
and selective estrogen receptormodulators andbisphos-
phonate formaintenance of bonemineral density,may
be also selected. A plan for treatmentover a1-year period
should be made, and adjustments may be made after
1 year with consideration given to individual needs,
benefits and risks based on results of examination.
Clinicians should become experts in tailoringHRT
to accord with the characteristics and needs of each
woman.
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